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NZB  mice develop a progressive autoimmune  disease resembling human 
systemic lupus erythematosus (1-3)  in many respects.  The natural history of 
this  disease  is characterized  by the development of  hemolytic anemia, spleno- 
megaly,  glomerulonephritis, and  numerous  autoantibodies  (4-5). Humoral 
immune responses to a number of  antigens have been found to be abnormal in 
NZB mice (4-8)  and induction  of  tolerance  to  soluble  protein  antigens to  be more 
difficult  in NZB than in other strains  (9).  A variety  of  mechanisms have been 
proposed for these abnormalities (10-14).  In older mice, T-cell  functions like 
mitogen responsiveness (15),  graft-versus-host  reactivity  (16),  and cell-mediated 
cytotoxicity  (17-20)  have generally been decreased,  although in a recent report 
(21)  the level  of  some of  these functions  in the NZB strain  has been observed to 
be within the range of  normal. 
In previous investigations  (17-21)  the phenomenon of  cell-mediated  lymphol- 
ysis (CML)  I  in NZB mice has been examined by using targets  differing  at the 
major histocompatibility  complex (MHC) from NZB or against  virus-infected 
targets.  In the experiments reported  here,  the primary in vitro  CML  activity  of 
NZB  mice was investigated against syngeneic targets and against targets 
carrying the NZB  MHC  type (H-2  d) on a background differing  from NZB. In 
this  situation  primary in vitro  CML  activity  is  not generated by normal strains 
(22-26). In the present experiments  a significant  unidirectional CML  was 
unexpectedly  demonstrated against  H-2 identical  allogeneic  targets by NZB 
effector  cells.  These results  represent  the first  demonstration of  a CML reaction 
in a primary in vitro  system directed  against unmodified targets  which do not 
differ  from the cytotoxic  effectors  in the MHC.  They provide evidence for a 
qualitative  difference  in  T-cell  cytotoxic  function  between NZB mice and control 
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strains.  The  capacity  to respond  in this system against  H-2  identical  targets 
may be related to the autoimmune disease of NZB mice. 
Materials and Methods 
Mice.  Unless otherwise stated, 3-4 mo old male mice were used throughout the study.  NZB 
mice were obtained from the breeding colony of the Rheumatic Disease Unit of the University of 
Texas  Health  Science  Center  at  Dallas  (UTHSCD),  originally  obtained  from  Dr.  Marianne 
Bielschowsky,  the University of Dunedin,  New Zealand.  BALB/c, C57BL/6,  C57BL/10,  B10.D2, 
and DBA]2  mice were  obtained from The Jackson  Laboratory,  Bar Harbor,  Maine.  B6.C-H-2 d 
mice (HWl9) were a  generous gift of Doctors James Forman and Donald Bailey; all other strains 
used were bred and maintained in the colonies ofJ.  K.  at the UTHSCD. 
Skin Grafting.  Skin grafts were performed following the method described elsewhere (27). 
Serological Testing.  Serological tests for the presence of transplantation antigens were done 
according to Hauptfeld et al.  (28). 
Culture Media.  Hanks' balanced salt solution (HBSS) (Microbiological Associates, Walkers- 
ville, Md.) was used for washings. RPMI-1640 (Grand Island Biological Company, Grand Island, 
N.Y.) supplemented with 2 mM 1-glutamine (Gibco), 100 U/ml penicillin, 0.25 jag/ml Fungizone, 
100 mcg/ml streptomycin (Gibco), 5 x  10 -5 M 2-mercaptoethanol (Eastman Kodak Co., Rochester, 
N.Y.), fetal calf serum (Giboo) 10% and 25 mM Hepes buffer (Gibco) was used for all cultures. 
Cell Suspensions.  Mice were sacrificed by cervical dislocation and their spleens aseptically 
removed.  The  spleens  were  gently  teased  apart  in  cold  HBSS  and  the  resulting suspension 
aspirated through a  24-gauge needle. Clumps were allowed to settle for 5 min and removed. The 
suspension  was  washed  three  times  in  cold  HBSS,  and  after  the  third  wash  the  cells  were 
resuspended in RPMI-1640 and counted in a Coulter Counter, (Coulter Electronics, Inc., Hialeah, 
Fla.).  All suspensions were  adjusted to  4  x  106 cells/ml.  Viability,  as checked by trypan blue 
exclusion, was more than 95%. 
Stimulating  Cells.  Stimulator cells were irradiated with 3,000 rads (cesium source,  100 rads/ 
min). 
Preparation of Effector Cells.  1/2 ml of responding cells (2  x  l0  s cells) and 0.5 ml of stimulator 
cells  (2  ×  l0  s cells) were placed in 35  x  10 mm polystyrene Petri dishes (Corning,  no.  25,000, 
Corning Glass Works,  Science Products Div., Corning, N.Y.).  Each effector-stimulator combina- 
tion was set up in triplicate. The dishes were incubated in an atmosphere of 83% N2, 10% CO2, and 
7% 02 at 37°C on a  rocking platform for 5 days (29).  On the 5th day, target cells were added. 
Preparation of Target Cells.  4 ml of the spleen cell suspensions containing 16 x  106 cells were 
incubated in Falcon 3013  flasks (BioQuest,  BBL &  Falcon Products,  Becton, Dickinson &  Co., 
Cockeysville, Md.) at 37°C in an atmosphere of 5% CO2 in air for 5 days. 48 h  al~er the beginning 
of the  culture,  5  /~g/ml concanavalin A  was  added.  On  the  5th  day,  the  resulting blast cell 
suspension was washed in HBSS and 200-400 ~Ci sxCr-sodium chromate in 0.2 ml saline and 50 
~1 FCS was added to the pellet.  The cells were resuspended and incubated for 1 h  at 37°C with 
occasional shaking.  The cell suspension was then washed with HBSS,  resuspended in 1 ml of 
medium,  and layered  on a  Ficoll-Hypaque  solution with asp  gr of 1.077  (Isolymph,  Garrard- 
Schlesinger, Carle Place, N.Y.).  The gradient was spun at 1,200 rpm for 10 min at 4°C. The cells 
at  the  interface  were  harvested  with  a  Pasteur  pipette  and  washed  two  times  in  HBSS, 
resuspended in medium, and counted.  Viability of the cells was between 85 and 98% with most 
cells having a  large blastoid-like appearance. The suspension was then adjusted to 1  ×  105 cells/ 
ml. 
CML Assay.  104  target  cells  were  added  to  each  effector  cell  culture,  and  cultures  were 
incubated for 4 h  at 37°C in the gas mixture (83% N2, 10% CO2, 7% 02). Thereafter, the content of 
the Petri dishes was transferred to 12  ×  75-mm glass tubes and 2 ml of cold saline was added to 
stop the cytotoxic reaction. The tubes were shaken and spun down at 2,000 rpm for 5 min at 4°C. 
1 ml of the supernate was transferred to another tube and the radioactivity in both corresponding 
tubes was counted in a  gamma counter (Packard 5230,  Packard Instrument Co., Inc.,  Downers 
Grove, Ill.). The counts were corrected for the counter background counts and 51Cr release was 
calculated as percent of the total label incorporated according to the formula: 
% release =  (cpm 1/3 supernate) × 3  ×  100. 
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Specific lysis was defined as the total lysis in a culture minus the background lysis of the target 
cells lysed.  Background lysis was defined in every experiment as the release from target cells 
which were added to cultures of autologous effecter and autologous stimulator cells. Additionally, 
control cultures of effector cells with allogenic stimulator cells tested against targets autologous 
with the effectors were set up. 
Dose-Response Experiments.  Effector cell cultures were pooled on the 5th day  and the cell 
suspension washed two times in HBSS. The number of viable cells was determined by trypan blue 
exclusion. The desired number of potential effectors and 104 target cells in a  total vol of 1 ml of 
fresh medium were placed into Falcon 2054 tubes, centrifuged at 300 rpm for 2 rain,  and then 
incubated for 4 h  at 37°C  in an atmosphere of 5% CO2 in air. After 4 h,  2 ml of cold saline was 
added and 51Cr release determined. 
Anti-Thy I  Treatment.  Effector cell populations were pooled and washed two times in HBSS. 
The suspension was divided into two parts. One part was incubated with normal rabbit serum for 
30 min in an ice bath and the other part with a rabbit anti-mouse brain serum. This serum was a 
gift  of  Dr.  J.  Cambier  of  the  Department  of  Microbiology  UTHSCD.  Its  production  and 
characteristics  have been  described  elsewhere  (30).  After  30  min,  beth  the  suspensions were 
washed in HBSS  and incubated 30 rain at 37°C  in guinea pig serum diluted 1:4 with medium. 
Ai~rward,  the  suspensions were  washed  again  two  times  with  HBSS  and  viable  cells  were 
counted. The CML assay was performed in parallel with both suspensions in tubes as described 
above. 
Mitogen Stimulation.  50,000  viable cells  were incubated with PHA  (Difco  Laboratories, De- 
troit,  Mich. 1:500),  Con A (Pharmacia, Uppsala, Sweden, 5 ~tg/ml),  or  LPS (Difco,  E. coli  0111:134 
10 ~g/ml for  2 days in round bottom microtiter  plates. 1 /~Ci  of  [3H]thymidine was then added to 
the  cultures  and after  additional  6 h of  incubation,  the  cultures  were harvested with an automatic 
harvester (MASH II,  Microbiological  Associates)  and  radioactivity  counted in  a liquid  scintillation 
counter (Beckman Instruments, Inc.,  Fullerton,  Calif.). 
Statistical  Calculations.  Student's t  tests were performed by using a  program of the Medical 
Computing Resources Center, UTHSC at Dallas, on a  DEC 10 computer. 
Results 
CML of NZB (H-2  ~ against BALB/c (H-2d).  Table I shows the results of an 
experiment, in which CML reactions of NZB mice of two different ages, 3 and 10 
mo,  against  H-2  identical  BALB/c  and  H-2  disparate  C57BL/6  mice  were 
examined.  The  NZB mice did not generate  CML activity against  each other, 
nor did BALB/c effectors react against NZB targets.  In striking contrast,  NZB 
mice, both young and old, generated a significant CML reaction against BALB/c 
targets.  The fact that BALB/c exerted a  strong CML reaction against C57BL/6 
target cells indicated that the cytotoxic effector function of BALB/c was normal. 
To  verify  the  unexpected  finding  of primary  in  vitro  CML  against  H-2 
identical  targets by NZB effectors, five similar experiments  were carried out. 
The results  are summarized  in Table II.  In none of 12  CML tests of BALB/c 
effector cells  against  NZB  targets,  6  of these  against  target  cells  of young 
animals and 6 against target cells of old animals,  did BALB/c generate specific 
lysis of more than 10%, the mean specific release of all 12 reactions being 2.0 _+ 
2.1%. In contrast,  10 of 12 NZB versus BALB/c reactions yielded more than 10% 
specific lysis. The mean specific release was 26.5 _+ 5.1%. The difference between 
the specific lysis obtained by NZB against BALB/c and that of BALB/c against 
NZB,  is highly  significant  (P  <  0.001,  Student's t  test).  No significant  CML 
reactivity was observed between old and young NZB. 
Dose-Response Experiments.  To establish that the NZB anti-H-2 d cytotoxic 
effect was caused by cells  and  not by a  transferred  soluble factor,  two dose- 
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TABLE  I 
Primary in Vitro CML of NZB Mice against BALB/c 
Effector  Stimulator  Target  Release*  Specific 
release 
% 
BALB/c  BALB/c  BALB/c  24.4  _+ 2.2 
C57BL/6  73.6  -  1.2 
NZB Old*  53.0  -+ 2.3 
NZB Young§  55.8  _  4.2 
BALB/c  C57BL/6  C57BL/6  65.2  _+  1.1 
C57BL/6  20.4  _+ 0.6 
NZB Old  56.0  _+  5.6 
NZB Young  71.9  _+  1.2 
BALB/6  NZB Old  NZB Old  34.5  __ 2.0 
C57BL/6  66.8  __ 4.0 
NZB Old  32.2  _+  1.3 
NZB Young  42.5  _  3.8 
BALB/c  NZB Young  NZB Young  35.4  _+ 3.8 
C57BL/6  76.9  _+  1.2 
NZB Old  27.2  _+ 0.5 
NZB Young  28.3  _+  1.7 
% 
49.2 
28.6 
31.4 
44.8 
35.6 
51.5 
2.3 
34.6 
10.3 
7.1 
48.6 
-1.1 
* Mean and standard error of  the mean of  triplicate  determinations. 
* 10 mo old. 
§ 3 mo old. 
TABLE  II 
Primary in Vitro CML of NZB Mice of Different Ages against BALB/c 
Effector  Stimulator  Target  Specific  release* 
% 
C57BL/6  BALB/c  BALB/c  52.4  _+ 4.9 
BALB/c  C57BL/6  C57BL/6  46.5  _  1.6 
C57BL/6  NZB Old*  NZB Old  40.0  +_ 3.9 
C57BL/6  NZB Young§  NZB Young  42.2  -+ 5.5 
NZB Old  BALB/c  BALB/c  22.8  _+ 4.9 
P  < o.oo511 
BALB/c  NZB Old  NZB Old  4.5 _+  1.1 
NZB Young  BALB/c  BALB/c  30.3  -+ 6.2  P  <  0.001l{ 
BALB/c  NZB  Young  NZB  Young  0.3 _ 3.9 
NZB  Old  NZB  Young  NZB  Young  -1.0 _ 2.2 
NZB  Young  NZB  Old  NZB  Old  7.2 _ 2.4 
* Mean and standard error 
* 9-11 mo of  age. 
§ 2-4 mo of  age. 
II Student's t  test. 
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EXPERIMENT 17 
Dependency of the NZB anti-H-2 d reaction on the effector/target cell ratio. 
the reaction of NZB against HW19 (a congenic line, carrying H-2 d, derived from 
BALB/c on a  C57BL/6 background);  in the second experiment  the  NZB anti- 
BALB/c reaction  was  tested.  The  amount  of label  released  from  a  constant 
number  of targets  (104  )  in  both  experiments  was  clearly  dependent  on  the 
number of viable effector cells added,  indicating  that the cytotoxic effect was 
exerted by cells. 
CML of NZB  against Other H-2 ~ Strains.  In subsequent experiments,  the 
CML reactions of NZB against other H-2 d strains were tested. Table III gives a 
representative  experiment  of this  series.  As  expected,  no  significant  specific 
release was observed in primary  in vitro cultures  set up between the normal 
H-2 ~ carrying strains DBAJ2, B10.D2, and BALB/c. Also, none of these strains 
reacted  against  NZB,  although  they  did  react  with  the H-2  different  target 
C57BL/10.  In contrast,  as observed above with the BALB/c target,  NZB cells 
reacted against all tested H-2 d strains,  indicating that the unidirectional CML 
activity of NZB against H-2 d targets  was not restricted to the BALB/c H-2 ~. 
These results were confirmed in two further experiments  by using the strain 
HW19 in addition to the other strains. 
Cross-Reactivity  of  NZB  Effector  Cells  on  Different  H-2 d  Targets.  The 
specificity of the NZB effector cells obtained after BALB/c H-2 d primary in vitro 
sensitization  was  investigated  in  the  experiment  shown  in  Table  IV.  NZB 
effectors,  sensitized  with  BALB/c cells,  were tested against  BALB/c,  DBA/2, 
B10.D2,  and  C57BL/10  targets.  Significant  specific  lysis  of  all  three  H-2 d 
carrying  targets  was  observed,  indicating  cross-reactivity  in  this  respect.  A 
small  reaction  against  C57BL/10 was observed, raising  the  question of cross- 
reactivity with a  non-H-2  identical target.  This is examined below. Sensitiza- 
tion  with  C57BL/10  stimulators  as  a  control  resulted  in  lysis  only  of the 
appropriate target. In additional experiments, NZB effector cells sensitized with 
DBA/2 or B10.D2 showed the same H-2 ~ cross-reactions. 1440  CML  OF  NZB  MICE  AGAINST  H-2  IDENTICAL  STRAINS 
TABLE III 
Primary in Vitro CML of NZB against Three Different H-2 d Strains 
Effector  Stimulator  Target  Release*  Specific 
release 
% 
C57BL/10  C57BL/10  C57BL/10  23.7  ±  2.3 
B10.D2  66.7  _+  1.6 
BALB/c  63.1  ±  1.2 
DBA/2  63.5  ±  3.5 
NZB  68.2  ±  3.0 
B10.D2  NZB  NZB  24.4  _+ 2.2 
BALB/c  17.6  ±  1.6 
DBA/2  22.7  ±  1.9 
NZB  21.6  ±  0.2 
% 
43.0 
39.4 
39.8 
44.4 
2.8 
-4.0 
1.1 
B10.D2  B10.D2  B10.D2  17.0  ±  1.9  - 
BALB/c  18.6  ±  2.3  1.6 
DBA/2  22.0  ±  1.0  5.0 
NZB  52.1  _  1.6  35.0 
B10.D2  BALB/c  BALB/c  22.5  ±  2.6  3.0 
BALB/c  19.5  ±  0.3  - 
DBA/2  25.2  _+ 0.5  5.7 
NZB  75.2  _+  1.6  55.7 
B10.D2  DBA/2  DBA/2  25.4  ±  2.3  2.7 
BALB/c  22.5  +_ 1.9  -0.2 
DBA/2  22.7  ±  1.2  - 
NZB  68.9  ±  8.2  46.2 
* Mean and standard error of  the mean of  triplicate determinations. 
TABLE  IV 
Cross-Reactivity of NZB CML Effectors Sensitized by BALB/c on 
Different H-2 d Targets 
Specific 
Effector  Stimulator  Target  release 
% 
NZB  BALB/c  BALB/c  29.1 
NZB  C57BL/10  BALB/c  3.4 
NZB  BALB/c  DBA/2  21.8 
NZB  C57BL/10  DBA/2  6.3 
NZB  BALB/c  B10.D2  19.5 
NZB  C57BL/10  B10.D2  -  1.0 
NZB  BALB/c  C57BL/10  10.2 
NZB  C57BL/10  C57BL/10  45.7 
NZB  BALB/c  NZB  -  1.9 
NZB  C57BL/10  NZB  -2.5 U.  BOTZENHARDT,  J.  KLEIN,  AND  M.  ZIFF  1441 
TABLE  V 
Cross-Reactivity of NZB CML Effectors on the Congenic Lines BIO and BIOD2 
Effector  Stimulator  Target  Release*  Specific 
release 
%  % 
C57BL/10  C57BL/10  C57BL/10  25.4  __  0.8  - 
C57BL/10  B10.D2  22.1  _+ 0.5  -3.3 
B10.D2  C57BL/10  76.2  _+  2.9  50.8 
NZB  C57BL/10  79.5  _+ 2.4  54.1 
NZB  B10.D2  41.8  _+  11.2  16.4 
C57BL/10  B10.D2  B10.D2  57.8  _  3.4  37.0 
C57BL/10  NZB  81.9  _+  1.9  60.1 
B10.D2  C57BL/10  28.5  _+ 2.2  7.7 
B10.D2  B10.D2  20.8  _+  1.0  - 
NZB  C57BL/10  77.4  _  5.1  56.6 
NZB  B10.D2  65.8  __  6.3  45.0 
B10.D2  C57BL/10  NZB  15.0 _+ 0.8  -2.9 
B10.D2  NZB  19.9 + 1.8  2.0 
NZB  C57BL/10  19.1 _+ 1.3  1.2 
NZB  B10.D2  21.7 _+ 1.0  3.8 
NZB  NZB  17.9 --- 1.5  - 
* Mean and standard error of the mean of triplicate determinations. 
Confirmation  of  the  Presence  of  all  H-2 d  Transplantation  Antigens  in 
NZB.  One  possible  explanation  of the  unidirectional  cross-reactive  CML 
response of NZB against H-2 d targets would be that other H-2 a strains possess 
H-2 ~  antigens  which  are  lacking  in  NZB.  NZB  would  then  recognize  such 
antigens as foreign and react against cells expressing the complete set of H-2 d 
antigens. To establish the presence of all transplantation antigens in the NZB 
H-2 d complex, an F1  hybrid test was used.  10  (NZB  ×  C57BL/10)  F1  hybrids 
were grafted with B10.D2  skin. No graft rejection occurred during the observa- 
tion period of 100 days. Furthermore, serological tests for the presence of the 
H-2 d antigens H-2 and Ia were carried out by the direct cytotoxic test (28) and by 
the absorption method (28). All tested Ho2 ~ antigens were found to be expressed 
on NZB cells. So none of the antigens of the MHC, as defined either by the F1 
hybrid test or serologically is missing in NZB. 
Cross-Reactivity  of  NZB  Anti-H-2 ~  Effectors  on  H-2 b  Targets.  Another 
possible explanation of the NZB anti H-2 ~ CML is that the reaction is directed 
against minor histocompatibility (H) antigens recognized in the context of the 
H-2 ~ haplotype. If so, the reaction would be H-2 d restricted. Whether there is 
an  H.2  restriction  of  the  cytotoxic  effectors  in  NZB  was  investigated  in 
experiments utilizing two pairs of congenic lines: C57BL/10  (H-2 b) B10.D2  (H- 
2d),  and C57BL/6 (H-2 b)  and HWl9 (H.2%  The members of both pairs differ 
only in the H-2 region. If NZB cells sensitized with one congenic partner were 
to lyse targets of both congenic partners, the CML would not be H-2 restricted. 
If, on the other hand, only the H-2  identical target were to be lysed, the H-2 
complex would be  implicated in the  reaction.  Table  V  gives the  result  of a 
representative experiment and Table  VI the summary of three experiments. 1442  CML  OF  NZB  MICE  AGAINST  H-2  IDENTICAL  STRAINS 
TABLE  VI 
Cross-Reactivity  of NZB CML Effectors on the Congenic Lines 
C57BL/10 and BIO.D2: Summary of Three Experiments 
Effector  Stimulator  Target  Specific* 
release 
% 
NZB  C57BL/10  C57BL/10  50.3 _+ 6.4 
NZB  C57BL/10  B10.D2  36.0 -+ 12.5 
NZB  B10.D2  B10.D2  34.3 _ 8.7 
NZB  B10.D2  C57BL/10  15.3 _+ 6.2 
B10.D2  NZB  NZB  0.8  _+ 1.3 
* Mean and standard error of the mean of the specific lysis in three experi- 
ments. 
TABLE  VII 
Effect of Anti-Thy I  Serum Treatment on NZB Cytotoxic Reactions 
Specific  Effector  Stimulator  Target  Incubated  lysis 
% 
NZB  C57BL/10  C57BL/10  NRS  55.6 
NZB  C57BL]10  C57BL/10  Anti-Thy-1  -2.3 
NZB  B10.D2  C57BL/10  NRS  23.1 
NZB  B10. D2  C57BL/10  Anti-Thy-1  1.5 
NZB  C57BL/10  BI0.D2  NRS  60.4 
NZB  C57BL/10  BI0.D2  Anti-Thy-i  5.9 
NZB  BI0.D2  BI0.D2  NRS  30.6 
NZB  B10.D2  B10.D2  Anti-Thy-1  5.3 
After sensitization of NZB effectors with C57BL/10, lysis is observed not only of 
the  specific target,  C57BL/10,  but  also  of B10.D2  targets.  After  sensitization 
with B10.D2 stimulators,  lysis not only of B10.D2 but also of C57BL/10 targets 
occurred. Similar findings were obtained in the reactions involving the congenic 
combination C57BL/6 and HWl9.  These results suggest that NZB effector cells 
in  contrast  to  other  strains  may  not  be  H-2  restricted  in  their  cytotoxic 
aggression.  It should  be pointed out,  however,  that the  degree of lysis in  the 
cross-reactive reactions was smaller than in the specific reactions. 
T-Cell Character of the Cytotoxic Effector Cell.  To determine whether cyto- 
toxic T  cells were responsible for the  cytotoxic reactions demonstrated  above, 
NZB effector sensitized either with C57BL/10 or B10. D2 were incubated with an 
anti-Thy 1 serum. After incubation in guinea pig serum as complement source, 
the  effector  populations  were  tested  in  an  effector-to-target  ratio  of 35:1  on 
C57BL/10 and on B10.D2 targets. Additionally, the sensitized and the anti-Thy-1- 
treated sensitized populations were stimulated with the mitogens PHA, Con A, 
and  LPS.  Table  VII  gives the  results  of the  CML  tests.  All  CML  reactions 
whether H-2 allogeneic, NZB anti-H-2 d, or cross-reactive, were totally abolished U.  BOTZENHARDT,  J.  KLEIN,  AND  M.  ZIFF 
TABLE  VIII 
Selective T-Cell Elimination by Anti-Thy I Antiserum 
Treatment as Judged by Mitogen Stimulation 
Mitogen  Treatment  cpm ± SE* 
None  NRS  5,068 - 548 
None  Anti-Thy-I  1,810 ± 328 
PHA  NRS  17,926 ± 1,782 
PHA  Anti-Thy-1  2,169 ± 139 
Con A  NRS  9,003 ± 278 
Con A  Anti-Thy-1  2,139 ± 169 
LPS  NRS  18,336 ± 2,121 
LPS  Anti-Thy-1  22,710 ±  1,356 
* Mean and standard error  of  the mean of  triplicate  determinations. 
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TABLE  IX 
Cross-Reactivity of CeU-Mediated Lympholysis in NZB Mice* 
Target 
Effectors 
BALB/c Sensi-  NZB Sensitized 
tized  with BI0.D2  with BI0.D2 
C57BL/10  (H-2 b)  -0.7  7.8 
A.BY  (H-2 b)  -0.9  9.1 
B10.D2  (H-2 d)  -2.0  42.0 
DBA/2  (H-2 d)  -5.9  27.9 
B10.M  (H-T)  -6.9  14.1 
A.CA  (H-2 r)  -0.4  3.4 
B10.BR  (H-2 k)  -6.3  9.2 
CBA  (H-2 k)  -1.3  12.1 
B10.Q  (H-2q)  -0.5  10.4 
DBA/1  (H-2 q)  2.2  34.0 
B10.S  (H-2 s)  -2.6  19.1 
A.SW  (H-2  s)  -2.2  33.7 
* Lysis of targets  (a) identical to the stimulating cells,  (b) only H-2 
identical, (c) only background identical, and (d) nonidentical. Num- 
bers represent specific lysis in percent. 
by the  anti-Thy  1  treatment.  The  surviving  cells  in  the  antiserum  treated 
population showed normal responses to LPS (Table VIII). These results clearly 
indicate that the effector cell in the CML reactions described is a  T cell. 
Cross-reactivity  of NZB  Effectors  on  Other  BIO  Lines  and  on  Targets 
Allogenic  in the H-2 Region and in the Background.  The experiment shown 
in Table IX was done to determine whether NZB effector populations sensitized 
with H-2 d cells on the B10 background would cross-react with other congenic 1444  CML  OF  NZB  MICE  AGAINST  H-2  IDENTICAL  STRAINS 
B10  lines  expressing  other  H-2  haplotypes  than  H-2 d  and  H-2 ~,  like  H-2 f 
(B10.M),  H-2 ~  (B10.BR),  H.2q  (B10.Q),  and  1t-2"  (B10.S).  Additionally,  the 
question of whether NZB effector populations would recognize target cells which 
share neither the H-2  haplotype nor the background with the stimulating cell 
population was investigated.  In this experiment, therefore, the CML reactivity 
of the effector cell population against targets expressing the various H-2 types 
on either B10 or non-B10 backgrounds was compared.  Throughout  the experi- 
ment  the  CML of BALB/c effector cells was  assayed in  parallel  to  the  NZB 
effectors as a control. As expected, BALB/c, after sensitization with B10. D2, did 
not  generate  CML  against  any  of the  target  cells  used.  In  contrast,  NZB 
sensitized  with B10.D2  again  reacted with the B10.D2 target,  the sensitizing 
strain, and the DBA/2 target, carrying the H-2 d haplotype of the sensitizing cell 
on a different background.  However, there was also reaction with targets such 
as DBA/1 and A.SW carrying neither the H-2 haplotype, nor the background of 
the  sensitizing  strain.  These  results  indicate  that  NZB  cytoxic effector cells 
sensitized  with  B10.D2  have  the  capacity  to  cross-react  with  background 
antigens of a number of mouse strains carrying different H-2 haplotypes. They 
demonstrate  that  NZB effector cells,  after H-2 d  sensitization,  display a  rela- 
tively broad cross-reactivity which  is  not found  in the  normal  control  strain 
BALB/c. These findings were confirmed in a  similar experiment. 
Discussion 
The experiments reported here demonstrate that NZB mice after primary in 
vitro sensitization  with H-2  identical  cells exert CML activity against target 
cells  syngeneic  at  the  MHC  complex.  These  findings  provide  evidence  for  a 
qualitative T-cell abnormality in NZB mice compared to normal strains which 
do not generate cytotoxic cells under these conditions. The abnormal reactivity 
of NZB could be demonstrated as early as 2 mo of age, and was still present at 
12 mo of age. These findings indicate that the observed defect is either inherited 
or acquired early in life and continues after the emergence of the auteimmune 
disease. 
NZB effector cells, sensitized with one H-2 d strain,  exerted CML not only on 
targets identical to the strain used for sensitization,  but also against all other 
H-2 d  strains  tested.  However,  they  did  not  lyse  NZB  target  cells.  In  some 
experiments NZB effectors sensitized with H-2 d cells cross-reacted with non-H- 
2 d  targets  independently  of whether  these  targets  shared  the  genetic  back- 
ground with the stimulating  cell or not.  Additionally,  NZB anti-H-2 b effector 
cells were found to cross-react with H-2 d carrying target cells bearing the same 
genetic background. Thus, for example, NZB anti-C57BL/10 effecter cells were 
able to lyse C57BL/10 and B10.D2 target cells. 
Several  explanations  can  be considered  for  the  unexpected  observation  of 
CML activity of NZB against MHC identical strains and for the cross-reactions 
described. The first possibility is that the reactions were a nonspecific effect of 
the in vitro system used. This explanation is ruled out by control experiments 
involving responding cells derived from strains  other than  NZB. In all cases, 
these cells responded with the  specificity of the  CML reactions  as commonly 
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The  second  possiblity  is  that  the  NZB  anti.H-2 d  reactivity  noted  is  an 
autoimmune response to tt-2 d antigens. Such an explanation is unlikely since 
the same effector cells which lysed BALB/c targets did not lyse NZB targets. 
Were the NZB cytotoxic cells reacting with H-2 d  antigens,  the NZB targets 
would have  been  killed  to  the  same  extent as  the  BALB/c  and  other H-2 d 
targets. 
The third possibility is that NZB mice differ from BALB/c and other H-2 d 
strains (B10.D2,  HW19, DBA/2) in the H-2  complex and that, for example, the 
NZB anti-BALB/c reaction is an H-2 allogeneic reaction. Since the reaction is 
unidirectional, i.e. BALB/c responders do not kill NZB targets, one would have 
to presume that BALB/c and other 1-1-2  d  strains carry H-2  antigens that are 
absent in NZB. Such an assumption is contradicted by the finding that B10.D2 
skin grafts are permanently accepted by  (B10  ×  NZB)  F1  hybrids  (31). This 
observation was reconfirmed by grafting such FI hybrids derived by mating 
mice maintained in our animal colonies. The identity of the 11-2  haplotypes of 
NZB and B10.D2  is further supported by serological analysis which failed to 
reveal  any difference between the  two  strains,  and  by  the fact  that  grafts 
exchanged between B10.D2  and B10.NZB,  a  congenic line carrying the 1-1-2 
haplotype of NZB on B10 background, survived indefinitely (P. Ivanyi, personal 
communication). 
The fourth and,  in our view, the most likely explanation of the NZB anti- 
BALB/c reactivity is that the reaction is directed against minor H antigens and 
as such is 1-1-2 restricted. As originally demonstrated by Bevan (23) and Gordon 
and co-workers (24), minor H antigens can be recognized by T cells, but only in 
the context of the H-2  carried by the stimulating cells. The effector cells thus 
produced can then react with target cells sharing with the stimulators not only 
minor H  antigens, but also H-2  antigens.  Since the NZB strain was derived 
independently of other H-2 d  strains,  such as BALB/c,  B10.D2,  DBA/2,  HW19 
(1),  it very likely differs from them at a  number of H  loci. Furthermore, it is 
likely that BALB/c, B10.D2,  and DBA/2 share alleles at some of these loci and 
differ at these same loci from NZB  (22). One may, therefore, postulate that 
during culture of NZB cells with BALB/c stimulators, effector cells are gener- 
ated against  minor H  antigens.  However,  since both  strains  carry the H-2 d 
haplotype, the recognition of minor H antigens would occur in the context of  the 
H-2 d molecules. Such effectors would then be capable of lysing not only BALB/c 
target cells but also all targets that share with BALB/c the H-2 d haplotype and 
at least some of the minor H antigens. 
If the above explanation of the NZB anti-BALB/c reactivity is correct, then 
the observed reactivity is the first documented instance in which CML against 
minor  H  antigens  has  been  obtained  in  primary  in  vitro  culture.  In  the 
experiments of Bevan (23) and of Gordon et al. (24), CML to minor antigens was 
observed only after extensive in vivo preimmunization of the prospective donors 
of potential effector cells in CML.  Similar requirement for in vivo pre-sensiti- 
zation has also been observed in all other studies of CML against MIH antigens 
(25,  26).  What could be the reason for the unusual behavior of the NZB cells? 
The one striking difference between the NZB mice and other mouse strains is 
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number of abnormalities  in both humoral  and cellular  immunity.  Prominent 
among these is an increased resistance to tolerance induction (9). Expanded T- 
cell clones specific for minor H  antigens may exist in the NZB already in vivo, 
so that the observed reaction of NZB against 1-1-2 identical target cells would 
constitute a  secondary immune reaction against these antigens.  Alternatively, 
the NZB strain  might contain factors which nonspecifically enhance the CML 
reaction  through  activation  of cytotoxic  T  cells.  Experiments  to  solve  the 
question of the role of the NZB-H-2 complex as compared to background antigens 
in the  observed CML responses  utilizing  the  previously mentioned  B10.NZB 
line could not be carried out because this line has been discontinued (P. Ivanyi, 
personal communication,  M.  Mickov~, personal communication). 
The observation that in some experiments the NZB anti-B10.D2 effectors also 
reacted with targets  carrying haplotypes other than H-2 d can be explained in 
one of two ways. First, it is possible that CML to some minor H antigens is not 
H-2  restricted  in  the  NZB and  that the observed cross-reactivity of the  NZB 
anti-B10.D2 cells is caused by such antigens.  Second, one could argue that the 
cross-reactivity  reflects  similarity  between  certain  seemingly  unrelated  1-1-2 
haplotypes so that T-ceU effectors generated against a  minor H  antigen  in the 
context of H-2  d could, in the NZB, recognize this antigen in the context of  H-2q, 
for example. The reason why such cross-reactivity would be more apparent with 
NZB than other effectors could, again,  be related to the autoimmune status of 
the NZB mouse. An indication that NZB effectors might be more cross-reactive 
than  effectors  derived  from  other  mouse  strains  was  also  obtained  in  some 
allogeneic CML reactions carried out in this study. In most strain combinations 
CML cross-reactivity among unrelated H-2 haplotypes is relatively difficult to 
demonstrate  (32).  In  our experiments,  however, cross-reactivity of NZB anti- 
C57BL/10 effectors on B10.D2 target cells and of NZB anti-C57BL/10 effectors 
on B10.D2 target cells and of NZB effectors sensitized with C57BL/6 on HWl9 
target  cells  was  observed.  The  question  of what  causes  the  unusual  CML 
reactivity of NZB effector cells remains  open.  However, by investigating this 
question,  one may gain important  information  about the cellular mechanisms 
involved in autoimmunity. 
Summary 
T-cell cytotoxicity of NZB mice was tested after in vitro sensitization against 
a group of  H-2 identical strains (BALB/c, B10.D2, DBA/2, HWl9). A highly sig- 
nificant  and unexpected unidirectional  cell-mediated lympholysis (CML) reac- 
tion by the sensitized NZB effector cells on these targets was found. After sen- 
sitization  in vitro with stimulator cells of one H-2 d strain,  NZB effector cells 
(H-2 ~) lysed all other H-2 d targets and to a lesser degree, some non-H-2 d targets 
(C57BL/10,  DBA/1,  B10.Q,  CBA,  B10.S, A.SW).  NZB targets  were not lysed. 
Differences in the major histocompatibility region between NZB and other H-2 ~ 
strains could be excluded as a possible explanation for the observed reaction of 
NZB (H-2 d) against other [-1-2  d strains.  These results consequently represent 
the first description of a  primary in vitro CML directed against determinants 
not coded for in the major histocompatibility complex. The responsible effector 
cells are demonstrated to be T cells. The CML of NZB against H-2 identical tar- 
gets appears best explained by a reaction against minor histocompatibility anti- U.  BOTZENHARDT,  J.  KLEIN,  AND  M.  ZIFF  1447 
gens.  This,  and the observed cross-reactions, would indicate that the cytotoxic 
T-cell system in NZB mice is not  subjected to restrictions  found in all normal 
mouse strains tested until now under similar conditions. It is suggested that this 
hyperreactivity is related to the autoimmune responsiveness of the NZB strain. 
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